

Cabozantinib for treating medullary thyroid cancer

Information for the public Published: 28 March 2018

www.nice.org.uk

Cabozantinib (Cometriq) is available on the NHS as a possible treatment for progressive medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease.

Information and support

NHS Choices may be a good place to find out more.

These organisations can give you advice and support:

- Butterfly Thyroid Cancer Trust, 01207 545 469
- <u>AMEND</u>, 01892 516 076
- Macmillan Cancer Support, 0808 808 0000
- <u>Cancer Research UK</u>, 0808 800 4040.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations. ISBN: 978-1-4731-2887-3